J&J agrees to slash Sirturo price in South Africa, prompting authorities to end antitrust probe

A storm of scrutiny relating to Johnson & Johnson’s pricing and patenting of its tuberculosis med bedaquiline (branded as Sirturo) is clearing up after reaching a fever pitch last year.

South African antitrust authorities have dropped an investigation they opened into J&J last summer after the drugmaker and its Janssen subsidiary filed for a secondary patent that sought to fend off generics until 2027.